Article
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.
Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology - 1 Aug 2022
Medhat Mohammed A, El-Kassas Mohamed, Karam-Allah Haidi, Al Shafie Ahmed, Abd-Elsalam Sherief, Moustafa Ehab, Hassany Sahar M, Salama Marwa, Abd Elghafar Mohamed S, Sayed Hamdy, Badr Mohamed, Kamal Dalia T, Shamseldeen Ahmed, Ossimi Ashima'a, Moaz Inas, Esmael Hossam El-Deen, Ezz Eldin Azza M, Ezzat Sameera, Abdelghaffar Hossam, Abdelghaffar Khaled
Abstract excerpt
BACKGROUND AND STUDY AIMS: Currently, there is no therapy approved for COVID-19. We evaluated the efficacy and safety of sofosbuvir/ledipasvir and nitazoxanide for the treatment of patients with COVID-19 infection. PATIENTS AND METHODS: A multicenter, open-label randomized controlled trial included one hundred and ninety patients with non-severe COVID-19 infection. Patients were randomized into three groups. All...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.